Letter to Editor
Erythropoietin dose and survival of hemodialysis patients
- Department of Social Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
- Zabol University of Medical Sciences, Zabol, Iran
- Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamedan, Iran
- Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran
- Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Correspondence to:
Mahdi Mohammadian,
Department of Social Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran.
Email:
amohamadii1361@gmail.com.
Published:
2017-07-28
Abstract
Chronic kidney disease (CKD) is known as a major health problem worldwide (Levey et al., 2007). The CKD is defined as a stage of disease in which the patient's kidney function is less than a half of normal capacity (2). If the kidney function is 10% to 15% less than the normal capacity, the patient has reached the End Stage Renal Disease (ESRD). At this stage, the kidney transplant or dialysis with hemodialysis or peritoneal dialysis is necessary for patient's survival (Levey et al., 2002).